Daniel Finke

Dr. Daniel Finke

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in Circulation
Verified
Journal Article
Closed access
LLLorenz H. Lehmann
Lorenz H. Lehmann
MHMarkus B. Heckmann
Markus B. Heckmann
GBGuillaume Bailly
Guillaume Bailly
DFDaniel Finke
Daniel Finke
Adrien ProcureurAdrien Procureur
Adrien Procureur
LBLauren A Baldassarre
Lauren A Baldassarre
BACKGROUND: Immune checkpoint inhibitors (ICIs) are approved for multiple cancers but can result in ICI-associated myocarditis, an infrequent but life-threatening condition. Elevations in cardiac biomarkers, specifically troponin-I (cTnI), troponin-T (cTnT), and creatine kinase (CK), are used for diagnosis. However, the association between temporal elevations of these biomarkers with disease trajectory and outcomes has not been established. METHODS: We analyzed the diagnostic accuracy and prognostic performances of cTnI, cTnT, and CK in patients with ICI myocarditis (n=60) through 1-year follow-up in 2 cardio-oncology units (APHP Sorbonne, Paris, France and Heidelberg, Germany). A total of 1751 (1 cTnT assay type), 920 (4 cTnI assay types), and 1191 CK sampling time points were available. Major adverse cardiomyotoxic events (MACE) were defined as heart failure, ventricular arrhythmia, atrioventricular or sinus block requiring pacemaker, respiratory muscle failure requiring mechanical ventilation, and sudden cardiac death. Diagnostic performance of cTnI and cTnT was also assessed in an international ICI myocarditis registry. RESULTS: Within 72 hours of admission, cTnT, cTnI, and CK were increased compared with upper reference limits (URLs) in 56 of 57 (98%), 37 of 42 ([88%] P =0.03 versus cTnT), and 43 of 57 ([75%] P <0.001 versus cTnT), respectively. This increased rate of positivity for cTnT (93%) versus cTnI ([64%] P <0.001) on admission was confirmed in 87 independent cases from an international registry. In the Franco–German cohort, 24 of 60 (40%) patients developed ≥1 MACE (total, 52; median time to first MACE, 5 [interquartile range, 2–16] days). The highest value of cTnT:URL within the first 72 hours of admission performed best in terms of association with MACE within 90 days (area under the curve, 0.84) than CK:URL (area under the curve, 0.70). A cTnT:URL ≥32 within 72 hours of admission was the best cut-off associated with MACE within 90 days (hazard ratio, 11.1 [95% CI, 3.2–38.0]; P <0.001), after adjustment for age and sex. cTnT was increased in all patients within 72 hours of the first MACE (23 of 23 [100%]), whereas cTnI and CK values were less than the URL in 2 of 19 (11%) and 6 of 22 (27%) of patients ( P <0.001), respectively. CONCLUSIONS: cTnT is associated with MACE and is sensitive for diagnosis and surveillance in patients with ICI myocarditis. A cTnT:URL ratio <32 within 72 hours of diagnosis is associated with a subgroup at low risk for MACE. Potential differences in diagnostic and prognostic performances between cTnT and cTnI as a function of the assays used deserve further evaluation in ICI myocarditis.

20 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DFDaniel Finke
Daniel Finke
MHMarkus B. Heckmann
Markus B. Heckmann
JSJanek Salatzki
Janek Salatzki
JRJohannes Riffel
Johannes Riffel
EHEsther Herpel
Esther Herpel
LLLorenz H. Lehmann
Lorenz H. Lehmann
Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment. Nevertheless, their increasing use leads to an increase of immune-related adverse events (irAEs). Among them, ICI-associated myocarditis (ICIM) is a rare irAE with a high mortality rate. We aimed to characterize the transcriptional changes of ICIM myocardial biopsies and their possible implications. Patients suspected for ICIM were assessed in the cardio-oncology units of University Hospitals Heidelberg and Kiel. Via RNA sequencing of myocardial biopsies, we compared transcriptional changes of ICIM (n = 9) with samples from dilated cardiomyopathy (DCM, n = 11), virus-induced myocarditis (VIM, n = 5), and with samples of patients receiving ICIs without any evidence of myocarditis (n = 4). Patients with ICIM (n = 19) showed an inconsistent clinical presentation, e.g., asymptomatic elevation of cardiac biomarkers (hs-cTnT, NT-proBNP, CK), a drop in left ventricular ejection fraction, or late gadolinium enhancement in cMRI. We found 3784 upregulated genes in ICIM (FDR < 0.05). In the overrepresented pathway ‘response to interferon-gamma’, we found guanylate binding protein 5 and 6 (compared with VIM: GBP5 (log2 fc 3.21), GBP6 (log2 fc 5.37)) to be significantly increased in ICIM on RNA- and protein-level. We conclude that interferon-gamma and inflammasome-regulating proteins, such as GBP5, may be of unrecognized significance in the pathophysiology of ICIM.

27 April 2022 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
JPJohn R. Power
John R. Power
JAJoachim Alexandre
Joachim Alexandre
ACArrush Choudhary
Arrush Choudhary
BOBenay Ozbay
Benay Ozbay
SHSalim S. Hayek
Salim S. Hayek
MPMilan Patel
Milan Patel

15 October 2024 in Circulation
Verified
Journal Article
Open access
CHChristoph Hofmann
Christoph Hofmann
ASAdrian Serafin
Adrian Serafin
OSOle M. Schwerdt
Ole M. Schwerdt
JFJohannes Fischer
Johannes Fischer
FSFlorian Sicklinger
Florian Sicklinger
MVMirko Voelkers
Mirko Voelkers
BACKGROUND: The myocardium adapts to ischemia/reperfusion (I/R) by changes in gene expression, determining the cardiac response to reperfusion. mRNA translation is a key component of gene expression. It is largely unknown how regulation of mRNA translation contributes to cardiac gene expression and inflammation in response to reperfusion and whether it can be targeted to mitigate I/R injury. METHODS: To examine translation and its impact on gene expression in response to I/R, we measured protein synthesis after reperfusion in vitro and in vivo. Underlying mechanisms of translational control were examined by pharmacological and genetic targeting of translation initiation in mice. Cell type–specific ribosome profiling was performed in mice that had been subjected to I/R to determine the impact of mRNA translation on the regulation of gene expression in cardiomyocytes. Translational regulation of inflammation was studied by quantification of immune cell infiltration, inflammatory gene expression, and cardiac function after short-term inhibition of translation initiation. RESULTS: Reperfusion induced a rapid recovery of translational activity that exceeds baseline levels in the infarct and border zone and is mediated by translation initiation through the mTORC1 (mechanistic target of rapamycin complex 1)–4EBP1 (eIF4E-binding protein 1)–eIF (eukaryotic initiation factor) 4F axis. Cardiomyocyte-specific ribosome profiling identified that I/R increased translation of mRNA networks associated with cardiac inflammation and cell infiltration. Short-term inhibition of the mTORC1-4EBP1-eIF4F axis decreased the expression of proinflammatory cytokines such as Ccl2 (C-C motif chemokine ligand 2) of border zone cardiomyocytes, thereby attenuating Ly6C hi monocyte infiltration and myocardial inflammation. In addition, we identified a systemic immunosuppressive effect of eIF4F translation inhibitors on circulating monocytes, directly inhibiting monocyte infiltration. Short-term pharmacological inhibition of eIF4F complex formation by 4EGI-1 or rapamycin attenuated translation, reduced infarct size, and improved cardiac function after myocardial infarction. CONCLUSIONS: Global protein synthesis is inhibited during ischemia and shortly after reperfusion, followed by a recovery of protein synthesis that exceeds baseline levels in the border and infarct zones. Activation of mRNA translation after reperfusion is driven by mTORC1/eIF4F-mediated regulation of initiation and mediates an mRNA network that controls inflammation and monocyte infiltration to the myocardium. Transient inhibition of the mTORC1-/eIF4F axis inhibits translation and attenuates Ly6C hi monocyte infiltration by inhibiting a proinflammatory response at the site of injury and of circulating monocytes.

1 January 2025 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
MHMarkus B. Heckmann
Markus B. Heckmann
JLJulia Lehmann
Julia Lehmann
DFDaniel Finke
Daniel Finke
FRFlorian Roll
Florian Roll
NFNorbert Frey
Norbert Frey
LLLorenz H. Lehmann
Lorenz H. Lehmann
Heckmann MB, et al. Int J Heart Fail. 2025 Apr;7(2):98-106. https://doi.org/10.36628/ijhf.2024.0056

18 August 2026 in British Journal of Pharmacology
Verified
Journal Article
Open access
MHMarkus B. Heckmann
Markus B. Heckmann
ZPZsanett Papdi
Zsanett Papdi
NSNils J. Strauch
Nils J. Strauch
DFDaniel Finke
Daniel Finke
MRMarc-Steffen Raab
Marc-Steffen Raab
LLLorenz H. Lehmann
Lorenz H. Lehmann
Background and Purpose: Myeloid cell leukaemia‐1 (MCL‐1) is an essential anti‐apoptotic protein and a promising therapeutic target in oncology. Early clinical studies of MCL‐1 inhibitors reported unexpected elevations in cardiac troponin, raising concerns about potential cardiotoxicity. Conventional murine models may incompletely capture human‐relevant cardiac effects due to species‐specific differences in MCL‐1 pharmacology. Experimental Approach: We investigated the cardiac effects of the selective MCL‐1 inhibitor MIK665 in a humanised MCL‐1 mouse model. Animals were treated once weekly and assessed for cardiac biomarkers, left ventricular function by echocardiography, and myocardial transcriptomic changes at peak treatment (Day 14) and after treatment cessation (Day 21). Bulk RNA sequencing was used to characterise differential gene expression, pathway enrichment and higher‐order transcriptional modules. Key Results: MIK665 treatment induced a time‐dependent increase in circulating cardiac troponin T without detectable impairment of left ventricular systolic function. Transcriptomic analysis revealed coordinated suppression of mitochondrial and contractile gene programmes during treatment, accompanied by activation of stress‐ and immune‐associated pathways. After treatment cessation, cardiac troponin levels declined and the myocardial transcriptome shifted towards a distinct recovery‐associated profile. Conclusions and Implications: Pharmacological MCL‐1 inhibition induced a cardiac biomarker and transcriptional stress response characterised by troponin release and dynamic myocardial transcriptomic remodelling. Additional functional and histological analyses did not reveal overt systolic dysfunction, strain‐detectable impairment, or increased fibrotic remodelling. These alterations are consistent with a largely reversible cardiac stress response rather than overt structural or functional cardiotoxicity. These findings support the use of refined, humanised preclinical models to improve translational cardiac safety assessment.